Amyloid burden and neural function in people at risk for Alzheimer's Disease

Neurobiology of Aging

Volumn 35, Issue 3, 2014, Pages 576-584

  Johnson, Sterling C ^a,b   Christian, Bradley T ^b   Okonkwo, Ozioma C ^a,b   Oh, Jennifer M ^a,b   Harding, Sandra ^a,b   Xu, Guofan ^b   Hillmer, Ansel T ^b   Wooten, Dustin W ^b   Murali, Dhanabalan ^b   Barnhart, Todd E ^b   Hall, Lance T ^b   Racine, Annie M ^b   Klunk, William E ^c   Mathis, Chester A ^c   Bendlin, Barbara B ^a,b   Gallagher, Catherine L ^a,b   Carlsson, Cynthia M ^a,b   Rowley, Howard A ^b   Hermann, Bruce P ^b   Dowling, N Maritza ^a,b   Asthana, Sanjay ^a,b   Sager, Mark A ^b   more..

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

AD risk; Alzheimer's disease; Amyloid imaging; Cognitive function; Glucose metabolism

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; FLUORODEOXYGLUCOSE F 18; GLUCOSE; PITTSBURGH COMPOUND B;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GLUCOSE METABOLISM; GRAY MATTER; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOOD DISORDER; NERVOUS SYSTEM FUNCTION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARIETAL LOBE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; SELF REPORT; SUPERIOR TEMPORAL GYRUS; THALAMUS;

AD RISK; ALZHEIMER'S DISEASE; AMYLOID IMAGING; COGNITIVE FUNCTION; GLUCOSE METABOLISM;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; COGNITION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GLUCOSE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; REGISTRIES; RISK FACTORS;

EID: 84889589925     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.09.028     Document Type: Article

References (57)

1. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
2. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
3. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N.Engl. J. Med. 2012, 367:795-804. 10.1056/NEJMoa1202753.
4. Bendlin B.B., Ries M.L., Canu E., Sodhi A., Lazar M., Alexander A.L., Carlsson C.M., Sager M.A., Asthana S., Johnson S.C. White matter is altered with parental family history of Alzheimer's disease. Alzheimers Dement. 2010, 6:394-403. 10.1016/j.jalz.2009.11.003.
5. Chetelat G. Alzheimer disease: Abeta-independent processes-rethinking preclinical AD. Nat. Rev. Neurol. 2013, 9:123-124. 10.1038/nrneurol.2013.21.
6. Chételat G., La Joie R., Villain N., Perrotin A., de La Sayette V., Eustache F., Vandenberghe R. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage 2013, 2:356-365. http://dx.doi.org/10.1016/j.nicl.2013.02.006.
7. Chetelat G., Villemagne V.L., Pike K.E., Baron J.C., Bourgeat P., Jones G., Faux N.G., Ellis K.A., Salvado O., Szoeke C., Martins R.N., Ames D., Masters C.L., Rowe C.C. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 2010, 133:3349-3358. Australian Imaging, B., Lifestyle Study of Ageing Research, G. 10.1093/brain/awq187.
8. Christian B.T., Vandehey N.T., Floberg J.M., Mistretta C.A. Dynamic PET denoising with HYPR processing. J.Nucl. Med. 2010, 51:1147-1154. 10.2967/jnumed.109.073999.
9. Cohen A.D., Price J.C., Weissfeld L.A., James J., Rosario B.L., Bi W., Nebes R.D., Saxton J.A., Snitz B.E., Aizenstein H.A., Wolk D.A., Dekosky S.T., Mathis C.A., Klunk W.E. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J.Neurosci. 2009, 29:14770-14778. 10.1523/JNEUROSCI.3669-09.2009.
10. Dickerson B.C., Salat D.H., Bates J.F., Atiya M., Killiany R.J., Greve D.N., Dale A.M., Stern C.E., Blacker D., Albert M.S., Sperling R.A. Medial temporal lobe function and structure in mild cognitive impairment. Ann. Neurol. 2004, 56:27-35.
11. Edland S.D., Silverman J.M., Peskind E.R., Tsuang D., Wijsman E., Morris J.C. Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology 1996, 47:254-256.
12. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
13. Fleisher A.S., Chen K., Liu X., Ayutyanont N., Roontiva A., Thiyyagura P., Protas H., Joshi A.D., Sabbagh M., Sadowsky C.H., Sperling R.A., Clark C.M., Mintun M.A., Pontecorvo M.J., Coleman R.E., Doraiswamy P.M., Johnson K.A., Carpenter A.P., Skovronsky D.M., Reiman E.M. Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol. Aging 2013, 34:1-12. 10.1016/j.neurobiolaging.2012.04.017.
14. Floberg J.M., Mistretta C.A., Weichert J.P., Hall L.T., Holden J.E., Christian B.T. Improved kinetic analysis of dynamic PET data with optimized HYPR-LR. Med. Phys. 2012, 39:3319-3331. 10.1118/1.4718669.
15. Furst A.J., Lal R.A. Amyloid-beta and glucose metabolism in Alzheimer's disease. J.Alzheimers Dis. 2011, 26(Suppl 3):105-116. 10.3233/JAD-2011-0066.
16. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
17. Honea R.A., Swerdlow R.H., Vidoni E.D., Goodwin J., Burns J.M. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 2010, 74:113-120. 10.1212/WNL.0b013e3181c918cb.
18. Honea R.A., Swerdlow R.H., Vidoni E.D., Burns J.M. Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology 2011, 76:822-829. 10.1212/WNL.0b013e31820e7b74.
19. Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., Thies B., Phelps C.H. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:257-262. 10.1016/j.jalz.2011.03.004.
20. Jack C.R., Vemuri P., Wiste H.J., Weigand S.D., Aisen P.S., Trojanowski J.Q., Shaw L.M., Bernstein M.A., Petersen R.C., Weiner M.W., Knopman D.S. Evidence for ordering of Alzheimer disease biomarkers. Arch. Neurol. 2011, 68:1526-1535. 10.1001/archneurol.2011.183.
21. Jacobs H.I., Van Boxtel M.P., Heinecke A., Gronenschild E.H., Backes W.H., Ramakers I.H., Jolles J., Verhey F.R. Functional integration of parietal lobe activity in early Alzheimer disease. Neurology 2012, 78:352-360. 10.1212/WNL.0b013e318245287d.
22. Jack C.R., Knopman D.S., Weigand S.D., Wiste H.J., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., Roberts R.O., Rocca W.A., Boeve B.F., Petersen R.C. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann. Neurol. 2012, 71:765-775. 10.1002/ana.22628.
23. Jagust W.J., Landau S.M. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J.Neurosci. 2012, 32:18227-18233. Alzheimer's Disease Neuroimaging, I. 10.1523/JNEUROSCI.3266-12.2012.
24. Jagust W.J., Bandy D., Chen K., Foster N.L., Landau S.M., Mathis C.A., Price J.C., Reiman E.M., Skovronsky D., Koeppe R.A. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010, 6:221-229. 10.1016/j.jalz.2010.03.003.
25. Knopman D.S., Jack C.R., Wiste H.J., Weigand S.D., Vemuri P., Lowe V., Kantarci K., Gunter J.L., Senjem M.L., Ivnik R.J., Roberts R.O., Boeve B.F., Petersen R.C. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78:1576-1582. 10.1212/WNL.0b013e3182563bbe.
26. Knopman D.S., Jack C.R., Wiste H.J., Weigand S.D., Vemuri P., Lowe V.J., Kantarci K., Gunter J.L., Senjem M.L., Mielke M.M., Roberts R.O., Boeve B.F., Petersen R.C. Selective Worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with beta-Amyloidosis. JAMA Neurol. 2013, 70:1030-1038. 10.1001/jamaneurol.2013.182.
27. La Rue A., Hermann B., Jones J.E., Johnson S., Asthana S., Sager M.A. Effect of parental family history of Alzheimer's disease on serial position profiles. Alzheimers Dement. 2008, 4:285-290. 10.1016/j.jalz.2008.03.009.
28. Landau S.M., Mintun M.A., Joshi A.D., Koeppe R.A., Petersen R.C., Aisen P.S., Weiner M.W., Jagust W.J. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012, 72:578-586. Alzheimer's Disease Neuroimaging, I. 10.1002/ana.23650.
29. Lim Y.Y., Ellis K.A., Pietrzak R.H., Ames D., Darby D., Harrington K., Martins R.N., Masters C.L., Rowe C., Savage G., Szoeke C., Villemagne V.L., Maruff P. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012, 79:1645-1652. 10.1212/WNL.0b013e31826e9ae6.
30. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J.Cereb. Blood Flow Metab. 1996, 16:834-840. 10.1097/00004647-199609000-00008.
31. Lopresti B.J., Klunk W.E., Mathis C.A., Hoge J.A., Ziolko S.K., Lu X., Meltzer C.C., Schimmel K., Tsopelas N.D., DeKosky S.T., Price J.C. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J.Nucl. Med. 2005, 46:1959-1972. doi:46/12/1959 [pii].
32. Lowe V.J., Kemp B.J., Jack C.R., Senjem M., Weigand S., Shiung M., Smith G., Knopman D., Boeve B., Mullan B., Petersen R.C. Comparison of 18F-FDG and PiB PET in cognitive impairment. J.Nucl. Med. 2009, 50:878-886. 10.2967/jnumed.108.058529.
33. Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 2003, 19:1233-1239.
34. Mathis C.A., Kuller L.H., Klunk W.E., Snitz B.E., Price J.C., Weissfeld L.A., Rosario B.L., Lopresti B.J., Saxton J.A., Aizenstein H.J., McDade E.M., Kamboh M.I., Dekosky S.T., Lopez O.L. Invivo assessment of amyloid-beta deposition in nondemented very elderly subjects. Ann. Neurol. 2013, 73:751-761. 10.1002/ana.23797.
35. Mielke M.M., Wiste H.J., Weigand S.D., Knopman D.S., Lowe V.J., Roberts R.O., Geda Y.E., Swenson-Dravis D.M., Boeve B.F., Senjem M.L., Vemuri P., Petersen R.C., Jack C.R. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 2012, 79:1570-1577. 10.1212/WNL.0b013e31826e2696.
36. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 2010, 67:122-131. 10.1002/ana.21843.
37. Mosconi L., Brys M., Switalski R., Mistur R., Glodzik L., Pirraglia E., Tsui W., De Santi S., de Leon M.J. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. U.S.A 2007, 104:19067-19072. 10.1073/pnas.0705036104.
38. Mosconi L., Mistur R., Switalski R., Brys M., Glodzik L., Rich K., Pirraglia E., Tsui W., De Santi S., de Leon M.J. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009, 72:513-520. 10.1212/01.wnl.0000333247.51383.43.
39. Mosconi L., Rinne J.O., Tsui W.H., Berti V., Li Y., Wang H., Murray J., Scheinin N., Nagren K., Williams S., Glodzik L., De Santi S., Vallabhajosula S., de Leon M.J. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc. Natl. Acad. Sci. U.S.A 2010, 107:5949-5954. 10.1073/pnas.0914141107.
40. Mosconi L., Rinne J.O., Tsui W.H., Murray J., Li Y., Glodzik L., McHugh P., Williams S., Cummings M., Pirraglia E., Goldsmith S.J., Vallabhajosula S., Scheinin N., Viljanen T., Nagren K., de Leon M.J. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol. Aging 2013, 34:22-34. 10.1016/j.neurobiolaging.2012.03.002.
41. Nichols L.M., Masdeu J.C., Mattay V.S., Kohn P., Emery M., Sambataro F., Kolachana B., Elvevag B., Kippenhan S., Weinberger D.R., Berman K.F. Interactive effect of apolipoprotein e genotype and age on hippocampal activation during memory processing in healthy adults. Arch. Gen. Psychiatry 2012, 69:804-813. 10.1001/archgenpsychiatry.2011.1893.
42. Oh H., Habeck C., Madison C., Jagust W. Covarying alterations in Abeta deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum. Brain Mapp 2012, 10.1002/hbm.22173.
43. Okonkwo O.C., Xu G., Dowling N.M., Bendlin B.B., Larue A., Hermann B.P., Koscik R., Jonaitis E., Rowley H.A., Carlsson C.M., Asthana S., Sager M.A., Johnson S.C. Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults. Neurology 2012, 78:1769-1776. 10.1212/WNL.0b013e3182583047.
44. Okonkwo O.C., Xu G., Oh J.M., Dowling N.M., Carlsson C.M., Gallagher C.L., Birdsill A.C., Palotti M., Wharton W., Hermann B.P., Larue A., Bendlin B.B., Rowley H.A., Asthana S., Sager M.A., Johnson S.C. Cerebral blood flow is diminished in asymptomatic middle-aged adults with maternal history of Alzheimer's disease. Cereb. Cortex 2012, 10.1093/cercor/bhs381.
45. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818. 10.1038/nn.2583.
46. Price J.C., Klunk W.E., Lopresti B.J., Lu X., Hoge J.A., Ziolko S.K., Holt D.P., Meltzer C.C., Dekosky S.T., Mathis C.A. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J.Cereb. Blood Flow Metab. 2005, 25:1528-1547.
47. Reiman E.M., Quiroz Y.T., Fleisher A.S., Chen K., Velez-Pardo C., Jimenez-Del-Rio M., Fagan A.M., Shah A.R., Alvarez S., Arbelaez A., Giraldo M., Acosta-Baena N., Sperling R.A., Dickerson B., Stern C.E., Tirado V., Munoz C., Reiman R.A., Huentelman M.J., Alexander G.E., Langbaum J.B., Kosik K.S., Tariot P.N., Lopera F. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012, 11:1048-1056. 10.1016/S1474-4422(12)70228-4.
48. Ridgway G.R., Henley S.M., Rohrer J.D., Scahill R.I., Warren J.D., Fox N.C. Ten simple rules for reporting voxel-based morphometry studies. Neuroimage 2008, 40:1429-1435. 10.1016/j.neuroimage.2008.01.003.
49. Rodrigue K.M., Kennedy K.M., Devous M.D., Rieck J.R., Hebrank A.C., Diaz-Arrastia R., Mathews D., Park D.C. beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 2012, 78:387-395. 10.1212/WNL.0b013e318245d295.
50. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283. 10.1016/j.neurobiolaging.2010.04.007.
51. Sager M.A., Hermann B., La Rue A. Middle-aged children of persons with Alzheimer's Disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J.Geriatr. Psychiatry Neurol. 2005, 18:245-249.
52. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011, 7:280-292. 10.1016/j.jalz.2011.03.003.
53. Sperling R.A., Johnson K.A., Doraiswamy P.M., Reiman E.M., Fleisher A.S., Sabbagh M.N., Sadowsky C.H., Carpenter A., Davis M.D., Lu M., Flitter M., Joshi A.D., Clark C.M., Grundman M., Mintun M.A., Skovronsky D.M., Pontecorvo M.J. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normalolder individuals. Neurobiol. Aging 2013, 34:822-831. 10.1016/j.neurobiolaging.2012.06.014.
54. Swerdlow R.H. Brain aging, Alzheimer's disease, and mitochondria. Biochim. Biophys. Acta 2011, 1812:1630-1639. 10.1016/j.bbadis.2011.08.012.
55. Wilson A.A., Garcia A., Jin L., Houle S. Radiotracer synthesis from [(11)C]-iodomethane: a remarkably simple captive solvent method. Nucl. Med. Biol. 2000, 27:529-532.
56. Worsley K.J., Taylor J.E., Tomaiuolo F., Lerch J. Unified univariate and multivariate random field theory. Neuroimage 2004, 23(Suppl 1):S189-S195. 10.1016/j.neuroimage.2004.07.026.
57. Xiong C., Roe C.M., Buckles V., Fagan A., Holtzman D., Balota D., Duchek J., Storandt M., Mintun M., Grant E., Snyder A.Z., Head D., Benzinger T.L., Mettenburg J., Csernansky J., Morris J.C. Role of family history for Alzheimer biomarker abnormalities in the adult children study. Arch. Neurol. 2011, 68:1313-1319. 10.1001/archneurol.2011.208.